[EN]Background: Nowadays, nanoparticles (NPs) have evolved as multifunctional systems combining diferent custom
anchorages which opens a wide range of applications in biomedical research. Thus, their pharmacological involve‑
ments require more comprehensive analysis and novel nanodrugs should be characterized by both chemically and
biological point of view. Within the wide variety of biocompatible nanosystems, iron oxide nanoparticles (IONPs)
present mostly of the required features which make them suitable for multifunctional NPs with many biopharmaceu‑
tical applications.
Results: Cisplatin-IONPs and diferent functionalization stages have been broadly evaluated. The potential applica‑
tion of these nanodrugs in onco-therapies has been assessed by studying in vitro biocompatibility (interactions with
environment) by proteomics characterization the determination of protein corona in diferent proximal fuids (human
plasma, rabbit plasma and fetal bovine serum),. Moreover, protein labeling and LC–MS/MS analysis provided more
than 4000 proteins de novo synthetized as consequence of the nanodrugs presence defending cell signaling in dif‑
ferent tumor cell types (data available via ProteomeXchanges with identifed PXD026615). Further in vivo studies have
provided a more integrative view of the biopharmaceutical perspectives of IONPs.
Conclusions: Pharmacological proteomic profle diferent behavior between species and diferent afnity of protein
coating layers (soft and hard corona). Also, intracellular signaling exposed diferences between tumor cell lines
